The use of animal models in diabetes research

British Journal of Pharmacology

Volumn 166, Issue 3, 2012, Pages 877-894

  King, Aileen J F ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

animal models; type 1 diabetes; type 2 diabetes

Indexed keywords

DIPHTHERIA TOXIN; DOXYCYCLINE;

ALLOXAN DIABETES MELLITUS; AUTOIMMUNE DISEASE; BIOBREEDING RAT; C57BL 6 MOUSE; CELL FUNCTION; CELL REGENERATION; DIABETES MELLITUS; DIABETIC OBESITY; GENETIC ASSOCIATION; GERBIL; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULITIS; KNOCKOUT MOUSE; LEWIS RAT; LIPID DIET; MONOGENIC DISORDER; MULTIFACTORIAL INHERITANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PANCREAS INJURY; PANCREAS ISLET BETA CELL; PANCREAS RESECTION; PRIORITY JOURNAL; REVIEW; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; TRANSGENIC RAT; ZUCKER DIABETIC FATTY RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIETARY FATS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; OBESITY; STREPTOZOCIN;

EID: 84860845827     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01911.x     Document Type: Review

References (213)

1. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, et al,. (1996). Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12: 106-109.
2. Almind K, Kahn CR, (2004). Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. Diabetes 53: 3274-3285.
3. Andrikopoulos S, Rosella G, Gaskin E, Thorburn A, Kaczmarczyk S, Zajac JD, et al,. (1993). Impaired regulation of hepatic fructose-1,6-bisphosphatase in the New Zealand obese mouse model of NIDDM. Diabetes 42: 1731-1736.
4. Arndt T, Wedekind D, Weiss H, Tiedge M, Lenzen S, Hedrich HJ, et al,. (2009). Prevention of spontaneous immune-mediated diabetes development in the LEW.1AR1-iddm rat by selective CD8+ T cell transfer is associated with a cytokine shift in the pancreas-draining lymph nodes. Diabetologia 52: 1381-1390.
5. Bachmanov AA, Reed DR, Tordoff MG, Price RA, Beauchamp GK, (2001). Nutrient preference and diet-induced adiposity in C57BL/6ByJ and 129P3/J mice. Physiol Behav 72: 603-613.
6. Baek HS, Yoon JW, (1991). Direct involvement of macrophages in destruction of beta-cells leading to development of diabetes in virus-infected mice. Diabetes 40: 1586-1597.
7. Baeyens L, De BS, Lardon J, Mfopou JK, Rooman I, Bouwens L, (2005). In vitro generation of insulin-producing beta cells from adult exocrine pancreatic cells. Diabetologia 48: 49-57.
8. Bansal R, Ahmad N, Kidwai JR, (1980). Alloxan-glucose interaction: effect on incorporation of 14C-leucine into pancreatic islets of rat. Acta Diabetol Lat 17: 135-143.
9. Bellinger DA, Merricks EP, Nichols TC, (2006). Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications. ILAR J 47: 243-258.
10. Bock T, Pakkenberg B, Buschard K, (2003). Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52: 1716-1722.
11. Bodvarsdottir TB, Hove KD, Gotfredsen CF, Pridal L, Vaag A, Karlsen AE, et al,. (2010). Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 53: 2220-2223.
12. Bonner-Weir S, Trent DF, Honey RN, Weir GC, (1981). Responses of neonatal rat islets to streptozotocin: limited B-cell regeneration and hyperglycemia. Diabetes 30: 64-69.
13. Bonner-Weir S, Trent DF, Weir GC, (1983). Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71: 1544-1553.
14. Bonnevie-Nielsen V, Steffes MW, Lernmark A, (1981). A major loss in islet mass and B-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin. Diabetes 30: 424-429.
15. Breyer MD, Bottinger E, Brosius FC, Coffman TM, Fogo A, Harris RC, et al,. (2005). Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis 12: 128-145.
16. Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, et al,. (2009a). Mouse models of diabetic nephropathy. J Am Soc Nephrol 20: 2503-2512.
17. Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, et al,. (2009b). Mouse models of diabetic nephropathy. J Am Soc Nephrol 20: 2503-2512.
18. Buch T, Heppner FL, Tertilt C, Heinen TJAJ, Kremer M, Wunderlich FT, et al,. (2005). A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2: 419-426.
19. Buck DW, Jin DP, Geringer M, Jong HS, Galiano RD, Mustoe TA, (2011). The TallyHo polygenic mouse model of diabetes: implications in wound healing. Plast Reconstr Surg 128: 427e-437e.
20. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B, (2002). Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 282: E834-E842.
21. Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, et al,. (2008). Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes 57: 958-966.
22. Caquard M, Ferret-Bernard S, Haurogne K, Ouary M, Allard M, Jegou D, et al,. (2010). Diabetes acceleration by cyclophosphamide in the non-obese diabetic mouse is associated with differentiation of immunosuppressive monocytes into immunostimulatory cells. Immunol Lett 129: 85-93.
23. Carneiro FS, Giachini FR, Carneiro ZN, Lima VV, Ergul A, Webb RC, et al,. (2010). Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177. J Sex Med 7: 3620-3634.
24. Chakraborty G, Thumpayil S, Lafontant DE, Woubneh W, Toney JH, (2009). Age dependence of glucose tolerance in adult KK-Ay mice, a model of non-insulin dependent diabetes mellitus. Lab Anim (NY) 38: 364-368.
25. Chehab FF, Lim ME, Lu R, (1996). Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12: 318-320.
26. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al,. (1996). Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495.
27. Chen H, Zheng C, Zhang X, Li J, Li J, Zheng L, et al,. (2011). Apelin alleviates diabetes-associated endoplasmic reticulum stress in the pancreas of Akita mice. Peptides 32: 1634-1639.
28. Chen W, Zhou XB, Liu HY, Xu C, Wang LL, Li S, (2009). P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice. Br J Pharmacol 157: 724-735.
29. Cheng ZJ, Jiang YF, Ding H, Severson D, Triggle CR, (2007). Vascular dysfunction in type 2 diabetic TallyHo mice: role for an increase in the contribution of PGH2/TxA2 receptor activation and cytochrome p450 products. Can J Physiol Pharmacol 85: 404-412.
30. Cho YR, Kim HJ, Park SY, Ko HJ, Hong EG, Higashimori T, et al,. (2007). Hyperglycemia, maturity-onset obesity, and insulin resistance in NONcNZO10/LtJ males, a new mouse model of type 2 diabetes. Am J Physiol Endocrinol Metab 293: E327-E336.
31. Christianson SW, Shultz LD, Leiter EH, (1993). Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 42: 44-55.
32. Church C, Lee S, Bagg EA, McTaggart JS, Deacon R, Gerken T, et al,. (2009). A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS Genet 5: e1000599.
33. Church C, Moir L, McMurray F, Girard C, Banks GT, Teboul L, et al,. (2010). Overexpression of Fto leads to increased food intake and results in obesity. Nat Genet 42: 1086-1092.
34. Clee SM, Attie AD, (2007). The genetic landscape of type 2 diabetes in mice. Endocr Rev 28: 48-83.
35. Coleman DL, (1978). Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14: 141-148.
36. Cox RD, Church CD, (2011). Mouse models and the interpretation of human GWAS in type 2 diabetes and obesity. Dis Model Mech 4: 155-164.
37. Craighead JE, McLane MF, (1968). Diabetes mellitus: induction in mice by encephalomyocarditis virus. Science 162: 913-914.
38. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al,. (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31-40.
39. Declercq J, Kumar A, Van Diepen JA, Vroegrijk IOCM, Gysemans C, Di Pietro C, et al,. (2010). Increased +Â∥- cell mass by islet transplantation and PLAG1 overexpression causes hyperinsulinemic normoglycemia and hepatic insulin resistance in mice. Diabetes 59: 1957-1965.
40. Deeds MC, Anderson JM, Armstrong AS, Gastineau DA, Hiddinga HJ, Jahangir A, et al,. (2011). Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab Anim 45: 131-140.
41. Dekel Y, Glucksam Y, Elron-Gross I, Margalit R, (2009). Insights into modeling streptozotocin-induced diabetes in ICR mice. Lab Anim (NY) 38: 55-60.
42. Dolz M, Movassat J, Bailbe D, Le SH, Giroix MH, Fradet M, et al,. (2011). cAMP-secretion coupling is impaired in diabetic GK/Par rat beta-cells. A defect counteracted by GLP-1. Am J Physiol Endocrinol Metab 301: E797-E806.
43. Drel VR, Pacher P, Stavniichuk R, Xu W, Zhang J, Kuchmerovska TM, et al,. (2011). Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice. Int J Mol Med 28: 629-635.
44. Driver JP, Serreze DV, Chen YG, (2011). Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol 33: 67-87.
45. Dufrane D, van Steenberghe M, Guiot Y, Goebbels RM, Saliez A, Gianello P, (2006). Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and beta-cell plasticity. Transplantation 81: 36-45.
46. Duvillie B, Cordonnier N, Deltour L, ndoy-Dron F, Itier JM, Monthioux E, et al,. (1997). Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci U S A 94: 5137-5140.
47. Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, et al,. (2009). IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 106: 13998-14003.
48. Eizirik DL, Pipeleers DG, Ling Z, Welsh N, Hellerstrom C, Andersson A, (1994). Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc Natl Acad Sci U S A 91: 9253-9256.
49. Ellerman KE, Richards CA, Guberski DL, Shek WR, Like AA, (1996). Kilham rat triggers T-cell-dependent autoimmune diabetes in multiple strains of rat. Diabetes 45: 557-562.
50. Emamaullee JA, Merani S, Toso C, Kin T, Al-Saif F, Truong W, et al,. (2009). Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology 150: 2145-2152.
51. Fang RC, Kryger ZB, Buck DW, De la Garza M, Galiano RD, Mustoe TA, (2010). Limitations of the db/db mouse in translational wound healing research: is the NONcNZO10 polygenic mouse model superior? Wound Repair Regen 18: 605-613.
52. Fenner D, Odili S, Hong HK, Kobayashi Y, Kohsaka A, Siepka SM, et al,. (2011). Generation of N-ethyl-N-nitrosourea (ENU) diabetes models in mice demonstrates genotype-specific action of glucokinase activators. J Biol Chem 286: 39560-39572.
53. Fex M, Wierup N, Nitert MD, Ristow M, Mulder H, (2007). Rat insulin promoter 2-Cre recombinase mice bred onto a pure C57BL/6J background exhibit unaltered glucose tolerance. J Endocrinol 194: 551-555.
54. Fisher SJ, Shi ZQ, Lickley HL, Efendic S, Vranic M, Giacca A, (2001). Low-dose IGF-I has no selective advantage over insulin in regulating glucose metabolism in hyperglycemic depancreatized dogs. J Endocrinol 168: 49-58.
55. Flodstrom M, Tyrberg B, Eizirik DL, Sandler S, (1999). Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 48: 706-713.
56. Franconi F, Seghieri G, Canu S, Straface E, Campesi I, Malorni W, (2008). Are the available experimental models of type 2 diabetes appropriate for a gender perspective? Pharmacol Res 57: 6-18.
57. Fukaya N, Mochizuki K, Tanaka Y, Kumazawa T, Jiuxin Z, Fuchigami M, et al,. (2009). The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol 624: 51-57.
58. Gault VA, Kerr BD, Harriott P, Flatt PR, (2011). Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin Sci (Lond) 121: 107-117.
59. Girard CA, Wunderlich FT, Shimomura K, Collins S, Kaizik S, Proks P, et al,. (2009). Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest 119: 80-90.
60. Giroix MH, Irminger JC, Lacraz G, Noll C, Calderari S, Ehses J, et al,. (2011). Hypercholesterolaemia, signs of islet microangiopathy and altered angiogenesis precede onset of type 2 diabetes in the GotoÎÃô Kakizaki (GK) rat. Diabetologia 54: 2451-2462.
61. Goto Y, Kakizaki M, Masaki N, (1976). Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med 119: 85-90.
62. Grossman EJ, Lee DD, Tao J, Wilson RA, Park SY, Bell GI, et al,. (2010). Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PLoS ONE 5: e8749.
63. Grussner R, Nakhleh R, Grussner A, Tomadze G, Diem P, Sutherland D, (1993). Streptozotocin-induced diabetes mellitus in pigs. Horm Metab Res 25: 199-203.
64. Guberski DL, Thomas VA, Shek WR, Like AA, Handler ES, Rossini AA, et al,. (1991). Induction of type I diabetes by Kilham's rat virus in diabetes-resistant BB/Wor rats. Science 254: 1010-1013.
65. Guo K, Yu YH, Hou J, Zhang Y, (2010). Chronic leucine supplementation improves glycemic control in etiologically distinct mouse models of obesity and diabetes mellitus. Nutr Metab (Lond) 7: 57.
66. Habener JF, Kemp DM, Thomas MK, (2005). Minireview: transcriptional regulation in pancreatic development. Endocrinology 146: 1025-1034.
67. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM, (1997). Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A 94: 8878-8883.
68. Hanafusa T, Miyagawa J, Nakajima H, Tomita K, Kuwajima M, Matsuzawa Y, et al,. (1994). The NOD mouse. Diabetes Res Clin Pract 24 (Suppl.): S307-S311.
69. Hara M, Wang X, Kawamura T, Bindokas VP, Dizon RF, Alcoser SY, et al,. (2003). Transgenic mice with green fluorescent protein-labeled pancreatic beta -cells. Am J Physiol Endocrinol Metab 284: E177-E183.
70. Hartoft-Nielsen ML, Rasmussen AK, Bock T, Feldt-Rasmussen U, Kaas A, Buschard K, (2009). Iodine and tri-iodo-thyronine reduce the incidence of type 1 diabetes mellitus in the autoimmune prone BB rats. Autoimmunity 42: 131-138.
71. Haskell BD, Flurkey K, Duffy TM, Sargent EE, Leiter EH, (2002). The diabetes-prone NZO/HlLt strain. I. Immunophenotypic comparison to the related NZB/BlNJ and NZW/LacJ strains. Lab Invest 82: 833-842.
72. Hayashi K, Kojima R, Ito M, (2006). Strain differences in the diabetogenic activity of streptozotocin in mice. Biol Pharm Bull 29: 1110-1119.
73. He S, Chen Y, Wei L, Jin X, Zeng L, Ren Y, et al,. (2011). Treatment and risk factor analysis of hypoglycemia in diabetic rhesus monkeys. Exp Biol Med (Maywood) 236: 212-218.
74. Henson MS, O'Brien TD, (2006). Feline models of type 2 diabetes mellitus. ILAR J 47: 234-242.
75. von Herrath MG, Nepom GT, (2005). Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J Exp Med 202: 1159-1162.
76. von Herrath MG, Nepom GT, (2009). Animal models of human type 1 diabetes. Nat Immunol 10: 129-132.
77. von Herrath MG, Homann D, Gairin JE, Oldstone MBA, (1997). Pathogenesis and treatment of virus-induced autoimmune diabetes: novel insights gained from the RIP-LCMV transgenic mouse model. Biochem Soc Trans 25: 630-635.
78. von Herrath MG, Filippi C, Coppieters K, (2011). How viral infections enhance or prevent type 1 diabetes-from mouse to man. J Med Virol 83: 1672.
79. Herrera PL, Huarte J, Zufferey R, Nichols A, Mermillod B, Philippe J, et al,. (1994). Ablation of islet endocrine cells by targeted expression of hormone-promoter-driven toxigenes. Proc Natl Acad Sci U S A 91: 12999-13003.
80. Holmberg R, Refai E, Hoog A, Crooke RM, Graham M, Olivecrona G, et al,. (2011). Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci U S A 108: 10685-10689.
81. Hoppener JW, Oosterwijk C, van Hulst KL, Verbeek JS, Capel PJ, de Koning EJ, et al,. (1994). Molecular physiology of the islet amyloid polypeptide (IAPP)/amylin gene in man, rat, and transgenic mice. J Cell Biochem 55 (Suppl.): 39-53.
82. Hugill A, Shimomura K, Ashcroft FM, Cox RD, (2010). A mutation in KCNJ11 causing human hyperinsulinism (Y12X) results in a glucose-intolerant phenotype in the mouse. Diabetologia 53: 2352-2356.
83. Hummel KP, Dickie MM, Coleman DL, (1966). Diabetes, a new mutation in the mouse. Science 153: 1127-1128.
84. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J, (2003). Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 52: 1052-1055.
85. Ikeda H, (1994). KK mouse. Diabetes Res Clin Pract 24 (Suppl.): S313-S316.
86. Inada A, Arai H, Nagai K, Miyazaki J, Yamada Y, Seino Y, et al,. (2007). Gender difference in ICER Igamma transgenic diabetic mouse. Biosci Biotechnol Biochem 71: 1920-1926.
87. Ionut V, Liu H, Mooradian V, Castro AV, Kabir M, Stefanovski D, et al,. (2010). Novel canine models of obese prediabetes and mild type 2 diabetes. Am J Physiol Endocrinol Metab 298: E38-E48.
88. Jaidane H, Sane F, Gharbi J, Aouni M, Romond MB, Hober D, (2009). Coxsackievirus B4 and type 1 diabetes pathogenesis: contribution of animal models. Diabetes Metab Res Rev 25: 591-603.
89. Jansson L, Eizirik DL, Pipeleers DG, Borg LA, Hellerstrom C, Andersson A, (1995). Impairment of glucose-induced insulin secretion in human pancreatic islets transplanted to diabetic nude mice. J Clin Invest 96: 721-726.
90. Jederstrom G, Grasjo J, Nordin A, Sjoholm I, Andersson A, (2005). Blood glucose-lowering activity of a hyaluronan-insulin complex after oral administration to rats with diabetes. Diabetes Technol Ther 7: 948-957.
91. Jensen-Waern M, Andersson M, Kruse R, Nilsson B, Larsson R, Korsgren O, et al,. (2009). Effects of streptozotocin-induced diabetes in domestic pigs with focus on the amino acid metabolism. Lab Anim 43: 249-254.
92. Jonsson J, Carlsson L, Edlund T, Edlund H, (1994). Insulin-promoter- factor 1 is required for pancreas development in mice. Nature 371: 606-609.
93. Jorns A, Kubat B, Tiedge M, Wedekind D, Hedrich HJ, Kloppel G, et al,. (2004). Pathology of the pancreas and other organs in the diabetic LEW.1AR1/Ztm- iddm rat, a new model of spontaneous insulin-dependent diabetes mellitus. Virchows Arch 444: 183-189.
94. Jorns A, Gunther A, Hedrich HJ, Wedekind D, Tiedge M, Lenzen S, (2005). Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes 54: 2041-2052.
95. Jorns A, Rath KJ, Terbish T, Arndt T, Meyer ZV, Wedekind D, et al,. (2010). Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology 151: 3555-3565.
96. Jun HS, Yoon JW, (2003). A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev 19: 8-31.
97. Junger E, Herberg L, Jeruschke K, Leiter EH, (2002). The diabetes-prone NZO/Hl strain. II. Pancreatic immunopathology. Lab Invest 82: 843-853.
98. Jurgens HS, Neschen S, Ortmann S, Scherneck S, Schmolz K, Schuler G, et al,. (2007). Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction. Diabetologia 50: 1481-1489.
99. Kahn CR, (2003). Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes. Exp Diabesity Res 4: 169-182.
100. Kang Y, Chatterjee NK, Nodwell MJ, Yoon JW, (1994). Complete nucleotide sequence of a strain of coxsackie B4 virus of human origin that induces diabetes in mice and its comparison with nondiabetogenic coxsackie B4 JBV strain. J Med Virol 44: 353-361.
101. Kargar C, Ktorza A, (2008). Anatomical versus functional beta-cell mass in experimental diabetes. Diabetes Obes Metab 10 (Suppl. 4): 43-53.
102. Kawano K, Hirashima T, Mori S, Natori T, (1994). OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 24 (Suppl.): S317-S320.
103. Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, et al,. (2010). Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 16: 804-808.
104. Kim HR, Rho HW, Park BH, Park JW, Kim JS, Kim UH, et al,. (1994). Role of Ca2+ in alloxan-induced pancreatic beta-cell damage. Biochim Biophys Acta 1227: 87-91.
105. Kim JH, Stewart TP, Zhang W, Kim HY, Nishina PM, Naggert JK, (2005). Type 2 diabetes mouse model TallyHo carries an obesity gene on chromosome 6 that exaggerates dietary obesity. Physiol Genomics 22: 171-181.
106. King M, Pearson T, Rossini AA, Shultz LD, Greiner DL, (2008). Humanized mice for the study of type 1 diabetes and beta cell function. Ann N Y Acad Sci 1150: 46-53.
107. Kluth O, Mirhashemi F, Scherneck S, Kaiser D, Kluge R, Neschen S, et al,. (2011). Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure. Diabetologia 54: 605-616.
108. Knudsen LB, (2010). Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl. 64: 4-11.
109. Krentz AJ, Patel MB, Bailey CJ, (2008). New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 68: 2131-2162.
110. Kulkarni RN, Almind K, Goren HJ, Winnay JN, Ueki K, Okada T, et al,. (2003). Impact of genetic background on development of hyperinsulinemia and diabetes in insulin receptor/insulin receptor substrate-1 double heterozygous mice. Diabetes 52: 1528-1534.
111. Lavine RL, Voyles N, Perrino PV, Recant L, (1977). Functional abnormalities of islets of Langerhans of obese hyperglycemic mouse. Am J Physiol 233: E86-E90.
112. Leahy JL, Bonner-Weir S, Weir GC, (1988). Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 81: 1407-1414.
113. Lee JH, Yang SH, Oh JM, Lee MG, (2010). Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 62: 1-23.
114. Lee JY, Ristow M, Lin X, White MF, Magnuson MA, Hennighausen L, (2006). RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J Biol Chem 281: 2649-2653.
115. Lee MY, Shim MS, Kim BH, Hong SW, Choi R, Lee EY, et al,. (2011a). Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metab J 35: 130-137.
116. Lee SM, Yang H, Tartar DM, Gao B, Luo X, Ye SQ, et al,. (2011b). Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia 54: 1136-1146.
117. Lehtovirta M, Pietilainen KH, Levalahti E, Heikkila K, Groop L, Silventoinen K, et al,. (2010). Evidence that BMI and type 2 diabetes share only a minor fraction of genetic variance: a follow-up study of 23,585 monozygotic and dizygotic twins from the Finnish Twin Cohort Study. Diabetologia 53: 1314-1321.
118. Leiter EH, (2009). Selecting the 'right' mouse model for metabolic syndrome and type 2 diabetes research. Methods Mol Biol 560: 1-17.
119. Leiter EH, Reifsnyder PC, (2004). Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes 53 (Suppl. 1): S4-11.
120. Lenzen S, Tiedge M, Elsner M, Lortz S, Weiss H, Jorns A, et al,. (2001). The LEW.1AR1/Ztm-iddm rat: a new model of spontaneous insulin-dependent diabetes mellitus. Diabetologia 44: 1189-1196.
121. Liepinsh E, Vilskersts R, Zvejniece L, Svalbe B, Skapare E, Kuka J, et al,. (2009). Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. Br J Pharmacol 157: 1549-1556.
122. Like AA, Rossini AA, (1976). Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193: 415-417.
123. Lindstrom P, (2007). The physiology of obese-hyperglycemic mice [ob/ob mice]. Scientificworldjournal 7: 666-685.
124. Lukic ML, Stosic-Grujicic S, Shahin A, (1998). Effector mechanisms in low-dose streptozotocin-induced diabetes. Dev Immunol 6: 119-128.
125. Mack E, Ziv E, Reuveni H, Kalman R, Niv MY, Jorns A, et al,. (2008). Prevention of insulin resistance and beta-cell loss by abrogating PKCepsilon-induced serine phosphorylation of muscle IRS-1 in Psammomys obesus. Diabetes Metab Res Rev 24: 577-584.
126. Makhlouf L, Duvivier-Kali VF, Bonner-Weir S, Dieperink H, Weir GC, Sayegh MH, (2003). Importance of hyperglycemia on the primary function of allogeneic islet transplants. Transplantation 76: 657-664.
127. Malaisse WJ, Malaisse-Lagae F, Sener A, Pipeleers DG, (1982). Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc Natl Acad Sci U S A 79: 927-930.
128. Mather K, (2009). Surrogate measures of insulin resistance: of rats, mice, and men. Am J Physiol Endocrinol Metab 296: E398-E399.
129. Mathews CE, (2005). Utility of murine models for the study of spontaneous autoimmune type 1 diabetes. Pediatr Diabetes 6: 165-177.
130. Mathews CE, Leiter EH, (1999). Constitutive differences in antioxidant defense status distinguish alloxan-resistant and alloxan-susceptible mice. Free Radic Biol Med 27: 449-455.
131. Mathews CE, Langley SH, Leiter EH, (2002). New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation 73: 1333-1336.
132. Matsumoto S, (2011). Autologous islet cell transplantation to prevent surgical diabetes. J Diabetes 3: 328-336.
133. Matveyenko AV, Butler PC, (2006). Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J 47: 225-233.
134. Matveyenko AV, Gurlo T, Daval M, Butler AE, Butler PC, (2009). Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress. Diabetes 58: 906-916.
135. McGuinness OP, Ayala JE, Laughlin MR, Wasserman DH, (2009). NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. Am J Physiol Endocrinol Metab 297: E849-E855.
136. Mellert J, Hering BJ, Liu X, Brandhorst D, Brandhorst H, Brendel M, et al,. (1998). Successful islet auto- and allotransplantation in diabetic pigs. Transplantation 66: 200-204.
137. Mochizuki K, Fukaya N, Tanaka Y, Fuchigami M, Goda T, (2011). Treatment with the alpha-glucosidase inhibitor miglitol from the preonset stage in Otsuka Long-Evans Tokushima Fatty rats improves glycemic control and reduces the expression of inflammatory cytokine genes in peripheral leukocytes. Metabolism 60: 1560-1565.
138. Montane J, Bischoff L, Soukhatcheva G, Dai DL, Hardenberg G, Levings MK, et al,. (2011). Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. J Clin Invest 121: 3024-3028.
139. Montanya E, Tellez N, (2009). Pancreatic remodeling: beta-cell apoptosis, proliferation and neogenesis, and the measurement of beta-cell mass and of individual beta-cell size. Methods Mol Biol 560: 137-158.
140. Mordes JP, Bortell R, Blankenhorn EP, Rossini AA, Greiner DL, (2004). Rat models of type 1 diabetes: genetics, environment, and autoimmunity. ILAR J 45: 278-291.
141. Morel P, Kaufmann DB, Matas AJ, Tzardis P, Field MJ, Lloveras JK, et al,. (1991). Total pancreatectomy in the pig for islet transplantation. Technical alternatives. Transplantation 52: 11-15.
142. Movassat J, Calderari S, Fernandez E, Martin MA, Escriva F, Plachot C, et al,. (2007). Type 2 diabetes-a matter of failing beta-cell neogenesis? Clues from the GK rat model. Diabetes Obes Metab 9 (Suppl. 2): 187-195.
143. Muller YD, Golshayan D, Ehirchiou D, Wyss JC, Giovannoni L, Meier R, et al,. (2011). Immunosuppressive effects of streptozotocin-induced diabetes result in absolute lymphopenia and a relative increase of T-regulatory cells. Diabetes 60: 2331-2340.
144. Nerup J, Mandrup-Poulsen T, Helqvist S, Andersen HU, Pociot F, Reimers JI, et al,. (1994). On the pathogenesis of IDDM. Diabetologia 37 (Suppl. 2): S82-S89.
145. Neubauer N, Kulkarni RN, (2006). Molecular approaches to study control of glucose homeostasis. ILAR J 47: 199-211.
146. Niens M, Grier AE, Marron M, Kay TW, Greiner DL, Serreze DV, (2011). Prevention of 'Humanized' diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach. Diabetes 60: 1229-1236.
147. Nir T, Melton DA, Dor Y, (2007). Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117: 2553-2561.
148. Noda K, Melhorn MI, Zandi S, Frimmel S, Tayyari F, Hisatomi T, et al,. (2010). An animal model of spontaneous metabolic syndrome: Nile grass rat. FASEB J 24: 2443-2453.
149. O'Brien TD, (2002). Pathogenesis of feline diabetes mellitus. Mol Cell Endocrinol 197: 213-219.
150. Okada S, Saito M, Kinoshita Y, Satoh I, Kawaba Y, Hayashi A, et al,. (2010). Effects of cyclohexenonic long-chain fatty alcohol in type 2 diabetic rat nephropathy. Biomed Res 31: 219-230.
151. Ostenson CG, Efendic S, (2007). Islet gene expression and function in type 2 diabetes; studies in the Goto-Kakizaki rat and humans. Diabetes Obes Metab 9 (Suppl. 2): 180-186.
152. Park JS, Rhee SD, Kang NS, Jung WH, Kim HY, Kim JH, et al,. (2011). Anti-diabetic and anti-adipogenic effects of a novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1, 1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethano ne (KR-66344). Biochem Pharmacol 81: 1028-1035.
153. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G, (2009). Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373: 2027-2033.
154. Peschke E, Hofmann K, Bahr I, Streck S, Albrecht E, Wedekind D, et al,. (2011). The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus). Diabetologia 54: 1831-1840.
155. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, et al,. (1996). Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13: 18-19.
156. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, et al,. (1998). Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47: 358-364.
157. Pinhas-Hamiel O, Zeitler P, (2005). The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 146: 693-700.
158. Portha B, Levacher C, Picon L, Rosselin G, (1974). Diabetogenic effect of streptozotocin in the rat during the perinatal period. Diabetes 23: 889-895.
159. Portha B, Giroix MH, Serradas P, Gangnerau MN, Movassat J, Rajas F, et al,. (2001). beta-cell function and viability in the spontaneously diabetic GK rat: information from the GK/Par colony. Diabetes 50 (Suppl. 1): S89-S93.
160. Portha B, Lacraz G, Kergoat M, Homo-Delarche F, Giroix MH, Bailbe D, et al,. (2009). The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes? Mol Cell Endocrinol 297: 73-85.
161. Pozzilli P, Signore A, Williams AJ, Beales PE, (1993). NOD mouse colonies around the world-recent facts and figures. Immunol Today 14: 193-196.
162. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJ, (2011). Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 54: 1127-1135.
163. Reddy S, Wu D, Elliott RB, (1995). Low dose streptozotocin causes diabetes in severe combined immunodeficient (SCID) mice without immune cell infiltration of the pancreatic islets. Autoimmunity 20: 83-92.
164. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG, (2009). The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52: 1143-1151.
165. Roep BO, (2007). Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann N Y Acad Sci 1103: 1-10.
166. Rydgren T, Vaarala O, Sandler S, (2007). Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. J Pharmacol Exp Ther 323: 180-185.
167. Sandberg JO, Andersson A, Eizirik DL, Sandler S, (1994). Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 202: 543-548.
168. Sandler S, Swenne I, (1983). Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro. Diabetologia 25: 444-447.
169. Shafrir E, Ziv E, Kalman R, (2006). Nutritionally induced diabetes in desert rodents as models of type 2 diabetes: acomys cahirinus (spiny mice) and Psammomys obesus (desert gerbil). ILAR J 47: 212-224.
170. Sheshala R, Peh KK, Darwis Y, (2009). Preparation, characterization, and in vivo evaluation of insulin-loaded PLA-PEG microspheres for controlled parenteral drug delivery. Drug Dev Ind Pharm 35: 1364-1374.
171. Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K, (2000). Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 130: 495-504.
172. Shimada A, Maruyama T, (2004). Encephalomyocarditis-virus-induced diabetes model resembles 'fulminant' type 1 diabetes in humans. Diabetologia 47: 1854-1855.
173. Solomon TP, Sistrun SN, Krishnan RK, Del Aguila LF, Marchetti CM, O'Carroll SM, et al,. (2008). Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults. J Appl Physiol 104: 1313-1319.
174. Song J, Xu Y, Hu X, Choi B, Tong Q, (2010). Brain expression of Cre recombinase driven by pancreas-specific promoters. Genesis 48: 628-634.
175. Song WJ, Shah R, Hussain MA, (2009). The use of animal models to study stem cell therapies for diabetes mellitus. ILAR J 51: 74-81.
176. Srinivasan K, Ramarao P, (2007). Animal models in type 2 diabetes research: an overview. Indian J Med Res 125: 451-472.
177. Sullivan KA, Hayes JM, Wiggin TD, Backus C, Su OS, Lentz SI, et al,. (2007). Mouse models of diabetic neuropathy. Neurobiol Dis 28: 276-285.
178. Sullivan KA, Lentz SI, Roberts JL, Jr, Feldman EL, (2008). Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets 9: 3-13.
179. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN, (1988). Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37: 1163-1167.
180. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, et al,. (1995). Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44: 645-651.
181. Szkudelski T, (2001). The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50: 537-546.
182. Szollosi A, Nenquin M, Henquin JC, (2010). Pharmacological stimulation and inhibition of insulin secretion in mouse islets lacking ATP-sensitive K+ channels. Br J Pharmacol 159: 669-677.
183. Tai N, Yasuda H, Xiang Y, Zhang L, Rodriguez-Pinto D, Yokono K, et al,. (2011). IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol 139: 336-349.
184. Tian L, Gao J, Hao J, Zhang Y, Yi H, O'Brien TD, et al,. (2010). Reversal of new-onset diabetes through modulating inflammation and stimulating +Â∥- cell replication in nonobese diabetic mice by a dipeptidyl peptidase iv inhibitor. Endocrinology 151: 3049-3060.
185. Todd JA, Wicker LS, (2001). Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 15: 387-395.
186. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B, (2001). Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin- treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50: 1562-1570.
187. Tyrberg B, Andersson A, Borg LA, (2001). Species differences in susceptibility of transplanted and cultured pancreatic islets to the beta-cell toxin alloxan. Gen Comp Endocrinol 122: 238-251.
188. Vedtofte L, Bodvarsdottir TB, Gotfredsen CF, Karlsen AE, Knudsen LB, Heller RS, (2010). Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. Regul Pept 160: 106-114.
189. van der Werf N, Kroese FG, Rozing J, Hillebrands JL, (2007). Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 23: 169-183.
190. Wagner JE, Kavanagh K, Ward GM, Auerbach BJ, Harwood HJ, Jr, Kaplan JR, (2006). Old world nonhuman primate models of type 2 diabetes mellitus. ILAR J 47: 259-271.
191. im Walde SS, Dohle C, Schott-Ohly P, Gleichmann H, (2002). Molecular target structures in alloxan-induced diabetes in mice. Life Sci 71: 1681-1694.
192. Wallis RH, Wang K, Marandi L, Hsieh E, Ning T, Chao GY, et al,. (2009). Type 1 diabetes in the BB rat: a polygenic disease. Diabetes 58: 1007-1017.
193. Wang J, Wan R, Mo Y, Zhang Q, Sherwood LC, Chien S, (2010). Creating a long-term diabetic rabbit model. Exp Diabetes Res 2010: 289614.
194. Wang Q, Jin T, (2009). The role of insulin signaling in the development of beta-cell dysfunction and diabetes. Islets 1: 95-101.
195. Wang RN, Kloppel G, Bouwens L, (1995). Duct- to islet-cell differentiation and islet growth in the pancreas of duct-ligated adult rats. Diabetologia 38: 1405-1411.
196. Wang Z, Gleichmann H, (1998). GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 47: 50-56.
197. Wang ZV, Mu J, Schraw TD, Gautron L, Elmquist JK, Zhang BB, et al,. (2008). PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation. Diabetes 57: 2137-2148.
198. Wei L, Lu Y, He S, Jin X, Zeng L, Zhang S, et al,. (2011). Induction of diabetes with signs of autoimmunity in primates by the injection of multiple-low-dose streptozotocin. Biochem Biophys Res Commun 412: 373-378.
199. Weir GC, Marselli L, Marchetti P, Katsuta H, Jung MH, Bonner-Weir S, (2009). Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes. Diabetes Obes Metab 11 (Suppl. 4): 82-90.
200. Wicker LS, Clark J, Fraser HI, Garner VE, Gonzalez-Munoz A, Healy B, et al,. (2005). Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun 25 (Suppl.): 29-33.
201. Wijesekara N, Dai FF, Hardy AB, Giglou PR, Bhattacharjee A, Koshkin V, et al,. (2010). Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion. Diabetologia 53: 1656-1668.
202. Winzell MS, Ahren B, (2004). The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 (Suppl. 3): S215-S219.
203. Wise MH, Gordon C, Johnson RW, (1985). Intraportal autotransplantation of cryopreserved porcine islets of Langerhans. Cryobiology 22: 359-366.
204. Yang Y, Santamaria P, (2003). Dissecting autoimmune diabetes through genetic manipulation of non-obese diabetic mice. Diabetologia 46: 1447-1464.
205. Yang Y, Santamaria P, (2006). Lessons on autoimmune diabetes from animal models. Clin Sci (Lond) 110: 627-639.
206. Yoon JW, Jun HS, (2001). Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann N Y Acad Sci 928: 200-211.
207. Yoon JW, London WT, Curfman BL, Brown RL, Notkins AL, (1986). Coxsackie virus B4 produces transient diabetes in nonhuman primates. Diabetes 35: 712-716.
208. Yoshida S, Tanaka H, Oshima H, Yamazaki T, Yonetoku Y, Ohishi T, et al,. (2010). AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun 400: 745-751.
209. Yoshinari O, Igarashi K, (2011). Anti-diabetic effect of pyroglutamic acid in type 2 diabetic Goto-Kakizaki rats and KK- A y mice. Br J Nutr 106: 995-1004.
210. Zhang W, Kamiya H, Ekberg K, Wahren J, Sima AA, (2007). C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. Diabetes Metab Res Rev 23: 63-70.
211. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM, (1994). Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432.
212. Zhou C, Pridgen B, King N, Xu J, Breslow JL, (2011). Hyperglycemic Ins2AkitaLdlr-/- mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease. J Lipid Res 52: 1483-1493.
213. Ziv E, Shafrir E, Kalman R, Galer S, Bar-On H, (1999). Changing pattern of prevalence of insulin resistance in Psammomys obesus, a model of nutritionally induced type 2 diabetes. Metabolism 48: 1549-1554.